---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Mechanism of action"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Mechanism of action. Topics: Competitive antagonism of the bradykinin B2 receptor; Potency and selectivity in vitro, ex vivo, and in vivo; In vitro pharmacological profile of deucrictibant and its active metabolite; Molecular design: deuteration at a metabolic soft spot and absence of partial agonism; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Competitive antagonism of the bradykinin B2 receptor

> “Excessive bradykinin generation, as in HAE, promotes vascular permeability by activating the bradykinin B2 receptor in vascular endothelium cells, leading to plasma extravasation and subcutaneous or submucosal tissue swelling typical of an angioedema attack.”
> “treatment with deucrictibant, a novel, orally-bioavailable, highly potent and selective bradykinin B2 receptor antagonist is intended to block activation of the bradykinin B2 receptor by bradykinin, and, therefore, prevent or halt the angioedema process.”
> “Deucrictibant is an orally bioavailable competitive antagonist of the bradykinin B2 receptor with high affinity and high antagonist potency.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

### Potency and selectivity in vitro, ex vivo, and in vivo

> “Deucrictibant has been observed to be a potent inhibitor in vitro as assessed using human recombinant bradykinin B2 receptors (150 pM); ex vivo as studied against endogenous bradykinin B2 receptors in a human umbilical vein model (350 pM); and in vivo in the human bradykinin-challenge model (170 pM).”
> “Deucrictibant demonstrated over 4000-fold selectivity for the bradykinin B2 receptor when compared to approximately 170 other molecular targets, including the bradykinin-B1-receptor.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

### In vitro pharmacological profile of deucrictibant and its active metabolite

> “The present study describes the in vitro pharmacological characteristics of PHA-022121 and its active metabolite, PHA-022484 (M2-D).”
> “In mammalian cell lines, PHA-022121 and PHA-022484 show high affinity for the recombinant human bradykinin B2 receptor with Ki values of 0.47 and 0.70 nM, respectively, and potent antagonism of the human bradykinin B2 receptor with Kb values of 0.15 and 0.26 nM, respectively (calcium mobilization assay).”
> “potency at rat, mouse, rabbit and dog bradykinin B2 receptors is at least 100-fold lower than the potency at the human receptor for both compounds.”
> “It is about 20-fold more potent than icatibant at the human bradykinin B2 receptor as assessed using recombinant or endogenously expressed receptors.”

Source: [Lesage et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35086057/)

<a id="topic-2.1.2.6.1-4"></a>

### Molecular design: deuteration at a metabolic soft spot and absence of partial agonism

> “Metabolic soft spot stabilized by introduction of a deuterium atom”
> “2.4-fold lower molecular weight than icatibant”
> “Pure antagonistic activity at bradykinin B2 receptor”
> “no partial agonistic activity as icatibant was found to exert at high”
> “concentrations, as reached locally at site of injection”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.1-5"></a>

### Two oral formulations: immediate-release capsule for attacks and extended-release tablet for prophylaxis

> “Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment.”

Source: [Pharvaris CIIC Spring 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/evidence-supporting-combined-use-deucrictibant-ir-deucrictibant)

> “softgel capsule formulation”
> “rapid absorption in stomach and gut upon oral administration”
> “prolonged colonic absorption upon oral administration”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
